Wladzia Czuber-Dochan © ECCO

The N-ECCO Chair, Susanna Jäghult, opened the 16^th N-ECCO Network Meeting by welcoming 171 nurses from around the world. This was the second virtual Congress due to the COVID-19 pandemic.

Tim Raine  © ECCO

At the ECCO Congress 2022, Yves Panis and I had the great pleasure to present the new ECCO Guidelines on Therapeutics in Ulcerative Colitis. This work has been published as two papers in JCC: one dealing with the medical aspects of UC management, and one dealing with surgical strategies and the management of patients with acute severe UC. The guidelines were produced by a team of 33 clinicians and six patients, drawn from a total of 23 countries and supported by a group of professional methodologists, a librarian and, of course, the staff of the ECCO Office, including the indomitable Dauren Ramankulov. Yves and I were joined by Glen Doherty and Antonino Spinelli as co-ordinators of this large effort.

The second edition of the ECCO Postgraduate Course in IBD took place on February 17, 2022, on a virtual platform. The morning session reviewed patient management and treatment strategies, with contributions from numerous well-known speakers of ECCO, including the current and past presidents. 

Kostas Karmiris © ECCO

The 20^th ECCO IBD Intensive Course for Trainees was held virtually on February 16, 2022 as part of ECCO’s educational programme. This is ECCO’s oldest and most established course. This year, a total of 115 participants from 34 countries from Europe and elsewhere attended the course and were offered a comprehensive update on IBD. The course focused on pivotal insights into the medical management of IBD patients in an interactive manner.

Christian Maaser © ECCO

While the ECCO Basic Imaging Workshop in collaboration with ESGAR had to be postponed until next year’s ECCO Congress due to the need to change to a virtual format at rather short notice, the 9th ECCO Ultrasound Workshop – Advanced in collaboration with ESGAR did take place and proved a big success, bringing together 114 colleagues from 34 countries, including not just European countries but also, for example, the United States, Uruguay, Singapore, Japan, Korea, India and Australia.

Ravi Misra © Ravi Misra

The Epidemiological Committee (EpiCom) organised the 6^th EpiCom Workshop at the ECCO’22 Virtual Congress. The delegates were welcomed by EpiCom chair, Naila Arebi.

The opening presentation was a tandem talk by Naila Arebi and Valérie Pittet on core outcomes relevant to prognostic factors. The two different types of prognostic study, natural history and clinical course, were described, with identification of their strengths and weaknesses. Emphasis was placed on the importance of these studies in paving the way for personalised medicine by identifying high-risk groups and tailoring treatment accordingly. However, a significant limitation is the heterogeneity of outcomes, which limits comparison. Indeed, over 200 different outcomes have been described for Crohn’s Disease (CD) alone.

Shaji Sebastian  © ECCO

ClinCom Workshops are aimed at clinicians, surgeons and paediatricians and aim to provide an update on the latest clinical research trends in IBD. This year’s 8th ClinCom Workshop focused on two clinically relevant and practical topics.

Shaji Sebastian © ECCO

The ECCO Congress offers an ideal opportunity to learn, share and interact. This was also the main purpose of the 6th Basic ECCO: EduCational COurse for Industry, held on Wednesday, February 16, 2022. The course aimed to provide corporate and non-corporate members who have recently entered the field of IBD with an introduction to IBD, focussing on the clinical essentials and ‘need-to-knows’. Despite the obvious challenges relating to the format and the pandemic, 34 registrants attended the course.

Isabelle Cleynen  © ECCO

This year we celebrated the 10th edition of the SciCom Workshop. What better way to do this than by looking ahead at future therapeutic IBD targets?

To set the scene, Marc Ferrante took us through the limitations of current IBD therapies, including the therapeutic ceiling, lack of information on niche indications (e.g. anal fistula, pouchitis), drugs that become available despite many remaining questions, and safety and economic aspects. However, there is a bright future ahead, with many opportunities to explore, such as the need for novel drugs with better efficacy, thinking beyond anti-inflammatory drugs, head-to-head trials, using drugs more efficiently, considering other aetiological factors, precision medicine and more.

Sebastian Zeissig  © ECCO

One of the main goals of ECCO is to promote IBD-related basic and clinical research as well as to foster interaction and productive collaboration among European research groups working in the IBD field. To achieve this goal, ECCO supports numerous funding schemes with different scopes including ECCO Fellowships, Grants, and Travel Awards.